Keros Therapeutics (KROS) Stock Analysis & AI Equity Report
Keros Therapeutics (KROS) overview
Keros Therapeutics (KROS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 244m and operating profit of USD 67.6m; the year-end share price was 20.36 USD and market capitalisation was USD 398m. Keros Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Keros Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Keros Therapeutics
Keros Therapeutics is a clinical-stage biopharmaceutical company developing protein therapeutics for disorders linked to dysfunctional TGF-beta signaling. Its lead candidate, rinvatercept, is being developed for neuromuscular diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Elritercept is being developed for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis, under a worldwide license to Takeda outside mainland China, Hong Kong, and Macau.
Generate the Keros Therapeutics report
Keros Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Keros Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Keros Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.